Summary
2.42 -0.11(-4.23%)11/06/2024
Syros Pharmaceuticals Inc. (SYRS)
Syros Pharmaceuticals Inc. (SYRS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -4.61 | -4.23 | 24.26 | -54.37 | -52.49 | -13.46 | -95.26 | -98.67 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.42 | |
| Open | 2.59 | |
| High | 2.69 | |
| Low | 2.41 | |
| Volume | 262,670 | |
| Change | -0.12 | |
| Change % | -4.61 | |
| Avg Volume (20 Days) | 539,751 | |
| Volume/Avg Volume (20 Days) Ratio | 0.49 | |
| 52 Week Range | 1.43 - 8.17 | |
| Price vs 52 Week High | -70.34% | |
| Price vs 52 Week Low | 69.44% | |
| Range | -6.45 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 52 | |
| EBIDTA | -70,088,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 17.14 | |
| Book Value | 1.7120 | |
| Earnings Per Share | -1.5740 | |
| EPS Estimate Current Quarter | -0.4400 | |
| EPS Estimate Next Quarter | -0.4600 | |
| EPS Estimate Current Year | -1.5100 | |
| EPS Estimate Next Year | -1.9600 | |
| Diluted EPS (TTM) | -1.5740 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -4.8266 | |
| Return on asset (TTM) | -0.3779 | |
| Return on equity (TTM) | -1.2220 | |
| Revenue TTM | 21,385,000 | |
| Revenue per share TTM | 0.3620 | |
| Quarterly Revenue Growth (YOY) | 0.4880 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 15,093,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.1611 | |
| Revenue Enterprise Value | 6.9716 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 61,947,200 | |
| Shares Float | 51,355,426 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 4.77 | |
| Institutions (%) | 84.02 | |
11/04 11:00 EST - accesswire.com
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
11/03 11:00 EST - accesswire.com
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
11/02 11:00 EST - accesswire.com
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
10/31 14:21 EST - seekingalpha.com
Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
Syros Pharmaceuticals, Inc (NASDAQ:SYRS ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications Conley Chee - Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Phil Nadeau - TD Cowen Jason Butler - JMP Citizens Leah Cann - Brookline Capital Markets Operator Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
Syros Pharmaceuticals, Inc (NASDAQ:SYRS ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications Conley Chee - Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Phil Nadeau - TD Cowen Jason Butler - JMP Citizens Leah Cann - Brookline Capital Markets Operator Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10/31 07:30 EST - businesswire.com
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. “It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic synd.
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. “It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic synd.
10/27 11:00 EST - accesswire.com
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
10/26 11:00 EST - accesswire.com
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
10/24 07:08 EST - businesswire.com
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (interna.
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (interna.
10/21 11:00 EST - accesswire.com
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
10/19 11:00 EST - accesswire.com
Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
10/13 11:00 EST - accesswire.com
Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
10/09 11:00 EST - accesswire.com
Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.